Atlas Trials

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

Clinical trial NCT02876081 · WITHDRAWN

Trial details

NCT number
NCT02876081
Sponsor
Fondation Hôpital Saint-Joseph
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
SMALL CELL LUNG CARCINOMA
Start date
2017-09-01
Primary completion
2017-09-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.